1
|
Valentino LA, Allen G, Gill JC, Hurlet A, Konkle BA, Leissinger CA, Luchtman-Jones L, Powell J, Reding M, Stine K. Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors. Haemophilia 2013; 19:e151-66. [DOI: 10.1111/hae.12095] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/07/2012] [Indexed: 12/01/2022]
Affiliation(s)
- L. A. Valentino
- Hemophilia and Thrombophilia Center; Rush University Medical Center; Chicago; IL; USA
| | - G. Allen
- Hasbro Children's Hospital and Brown University Alpert School of Medicine; Providence; RI; USA
| | - J. C. Gill
- Medical College of Wisconsin and Blood Center of Wisconsin; Milwaukee; WI; USA
| | - A. Hurlet
- Mount Sinai Medical Center; New York; NY; USA
| | - B. A. Konkle
- Puget Sound Blood Center and the University of Washington; Seattle; WA; USA
| | - C. A. Leissinger
- Louisiana Center for Bleeding and Clotting Disorders; Tulane University Medical Center; New Orleans; LA; USA
| | | | - J. Powell
- University of California Davis; Sacramento; CA; USA
| | - M. Reding
- Center for Bleeding and Clotting Disorders; University of Minnesota; Minneapolis; MN; USA
| | - K. Stine
- University of Arkansas for Medical Sciences; Little Rock; AR; USA
| |
Collapse
|
2
|
Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, Villarroel M, Luchtman-Jones L, Quintana J, Santana VM. Frontline treatment of localized osteosarcoma without methotrexate: Results of the St. Jude Children's Research Hospital OS99 trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10036 Background: Standard treatment of osteosarcoma includes cisplatin and high-dose methotrexate (HD-MTX), but both agents are associated with significant toxicity and MTX administration requires complex pharmacokinetic monitoring. In our previous OS91 trial, the combination of carboplatin and ifosfamide with doxorubicin and HD-MTX yielded outcomes comparable to those of cisplatin-based regimens with less long-term toxicity in localized osteosarcoma. Methods: Between 1999 and 2006, we conducted a multi-institutional trial (OS99) to evaluate the activity of carboplatin, ifosfamide, and doxorubicin without HD-MTX in newly-diagnosed patients with localized osteosarcoma. Treatment comprised 12 cycles of chemotherapy given every 3 weeks: 3 consecutive cycles of carboplatin (dose targeted to AUC 8 mg/ml×min on day 1) and ifosfamide (2.65 g/m2 daily for 3 days) and one cycle of doxorubicin (25 mg/m2 daily for 3 days) followed by definitive surgery (week 12) and 2 additional cycles of carboplatin/ifosfamide and 3 cycles each of ifosfamide/doxorubicin and carboplatin/doxorubicin for a total of 35 weeks. The log rank test was used to compare survival and event-free survival (EFS) distributions. Results: A total of 72 eligible patients were enrolled. The median age was 13.4 years and 41 (57%) were male. The most common tumor site was the femur (n = 46; 64%). The median follow-up for survivors was 4.4 years. Forty of the 66 (60.6%) evaluable patients had good histologic response (tumor necrosis > 90%) to preoperative chemotherapy. There was no difference in EFS or survival distributions between OS99 and OS91. Four-year estimates of EFS were 68.1 ± 6.7% for OS99 compared to 70.2 ± 6.6% for OS91 (p = 0.89). The 4-year OS was 82.4% ± 5.7% for OS99 compared to 74.5% ± 6.3 for OS91 (p = 0.25). Conclusions: OS99 produced outcomes similar to cisplatin or HD-MTX containing regimens and offers an alternative treatment regimen especially for patients with renal compromise and institutions where pharmacokinetic monitoring of MTX is not available. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. C. Daw
- St. Jude Children's Research Hospital, Memphis, TN; Luis Calvo McKenna Hospital, Santiago, Chile; Washington University Medical School, St. Louis, MO
| | - M. D. Neel
- St. Jude Children's Research Hospital, Memphis, TN; Luis Calvo McKenna Hospital, Santiago, Chile; Washington University Medical School, St. Louis, MO
| | - B. N. Rao
- St. Jude Children's Research Hospital, Memphis, TN; Luis Calvo McKenna Hospital, Santiago, Chile; Washington University Medical School, St. Louis, MO
| | - C. A. Billups
- St. Jude Children's Research Hospital, Memphis, TN; Luis Calvo McKenna Hospital, Santiago, Chile; Washington University Medical School, St. Louis, MO
| | - J. Wu
- St. Jude Children's Research Hospital, Memphis, TN; Luis Calvo McKenna Hospital, Santiago, Chile; Washington University Medical School, St. Louis, MO
| | - J. J. Jenkins
- St. Jude Children's Research Hospital, Memphis, TN; Luis Calvo McKenna Hospital, Santiago, Chile; Washington University Medical School, St. Louis, MO
| | - M. Villarroel
- St. Jude Children's Research Hospital, Memphis, TN; Luis Calvo McKenna Hospital, Santiago, Chile; Washington University Medical School, St. Louis, MO
| | - L. Luchtman-Jones
- St. Jude Children's Research Hospital, Memphis, TN; Luis Calvo McKenna Hospital, Santiago, Chile; Washington University Medical School, St. Louis, MO
| | - J. Quintana
- St. Jude Children's Research Hospital, Memphis, TN; Luis Calvo McKenna Hospital, Santiago, Chile; Washington University Medical School, St. Louis, MO
| | - V. M. Santana
- St. Jude Children's Research Hospital, Memphis, TN; Luis Calvo McKenna Hospital, Santiago, Chile; Washington University Medical School, St. Louis, MO
| |
Collapse
|
3
|
Luchtman-Jones L, Valentino LA, Manno C. Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study. Haemophilia 2006; 12:82-6. [PMID: 16409180 DOI: 10.1111/j.1365-2516.2005.01171.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The long-term prophylactic administration of clotting factor concentrate in patients with haemophilia reduces bleeding events, slows joint deterioration, and improves quality of life. Prophylaxis can also be effective when used short-term to prevent or reduce bleeding associated with trauma, surgery, and athletic activities. While clinical trials are needed to establish the optimal length of prophylaxis following injury, several weeks and possibly months of treatment may be needed. Discontinuing therapy prematurely can result in rebleeding in the injured area.
Collapse
|
4
|
Jeha S, Razzouk B, Gaynon P, Kadota R, Rheingold S, Luchtman-Jones L, Arceci R, Fernandez M, Weitman S, Steinherz P. Phase II trials of clofarabine in pediatric acute leukemia. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6588] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Jeha
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - B. Razzouk
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - P. Gaynon
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - R. Kadota
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - S. Rheingold
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - L. Luchtman-Jones
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - R. Arceci
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - M. Fernandez
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - S. Weitman
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - P. Steinherz
- St. Jude Children’s Research Hosp, Memphis, TN; Children’s Hosp of Los Angeles, Los Angeles, CA; Children’s Hosp of San Diego, San Diego, CA; The Children’s Hosp of Philadelphia, Philadelphia, PA; St. Louis Children’s Hosp, St. Louis, MO; Johns Hopkins Hosp, Baltimore, MD; Ilex Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| |
Collapse
|
5
|
Jeha S, Razzouk B, Gaynon P, Kadota R, Rheingold S, Luchtman-Jones L, Arceci R, Fernandez M, Weitman S, Steinherz P. Clofarabine therapy for the treatment of relapsed or refractory pediatric acute leukemias. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8504] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Jeha
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - B. Razzouk
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - P. Gaynon
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - R. Kadota
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Rheingold
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - L. Luchtman-Jones
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - R. Arceci
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. Fernandez
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Weitman
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - P. Steinherz
- St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital of Los Angeles, Los Angeles, CA; Children's Hospital & Health Center, San Diego, CA; Children's Hospital of Philadelphia, Philadelphia, PA; Washington University Medical School at St. Louis, St. Louis, MO; Sidney Kimmel Comprehensive Care Ctr Johns Hopkins, Baltimore, MD; ILEX Products, Inc, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
6
|
Langford K, Luchtman-Jones L, Miller R, Walck D. Performance evaluation of the Sysmex XT-2000i automated hematology analyzer. Lab Hematol 2003; 9:29-37. [PMID: 12661825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
The Sysmex XT-2000i automated hematology analyzer was evaluated at Saint Louis Children's Hospital (SLCH), St. Louis, MO, USA. Complete blood count results from the Sysmex XT-2000i were compared to results from the Sysmex XE-2100 for 114 pediatric and adult patient samples. Manual differentials were performed on each specimen by 2 experienced medical technologists using guidelines established in the National Committee for Clinical Laboratory Standards (NCCLS) document H20-A. Carryover, precision, linearity, correlation, stability, and mixing-test studies were also performed. The XT-2000i results showed excellent correlation with the results from the XE-2100 for the following parameters: white blood cells; red blood cells; hemoglobin; hematocrit; mean corpuscular volume; mean corpuscular hemoglobin; mean corpuscular hemoglobin concentration; red blood cell distribution width by standard deviation; red blood cell distribution width by coefficient of variation; mean platelet volume; platelets; percent neutrophils, lymphocytes, monocytes, eosinophils, and basophils; and reticulocyte percent and number. In our evaluation of the XT-2000i the correlation coefficients for all complete blood counts and differential parameters compared well with those of the XE-2100. We concluded that the XT-2000i demonstrated comparable analytical performance to its predecessor, the XE-2100.
Collapse
Affiliation(s)
- K Langford
- Saint Louis Children's Hospital Core Laboratory/Hematology, St. Louis, Missouri 63110-1077, USA.
| | | | | | | |
Collapse
|
7
|
Orringer EP, Casella JF, Ataga KI, Koshy M, Adams-Graves P, Luchtman-Jones L, Wun T, Watanabe M, Shafer F, Kutlar A, Abboud M, Steinberg M, Adler B, Swerdlow P, Terregino C, Saccente S, Files B, Ballas S, Brown R, Wojtowicz-Praga S, Grindel JM. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA 2001; 286:2099-106. [PMID: 11694150 DOI: 10.1001/jama.286.17.2099] [Citation(s) in RCA: 143] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
CONTEXT Sickle cell disease (SCD) can cause severe painful episodes that are often thought to be caused by vaso-occlusion. The current therapy for these uncomplicated painful episodes includes hydration, oxygen, and analgesics. Purified poloxamer 188 may increase tissue oxygenation and thereby reduce inflammation, pain, and the overall duration of such painful episodes in patients with SCD. OBJECTIVE To compare the duration of painful episodes in patients with SCD treated with purified poloxamer 188 to that of similar episodes experienced by patients who receive a placebo. DESIGN AND SETTING Randomized, double-blind, placebo-controlled, intention-to-treat trial conducted between March 1998 and October 1999 in 40 medical centers in the United States. PARTICIPANTS Two hundred fifty-five patients with SCD (aged 9-53 years) who had a painful episode sufficiently severe to require hospitalization and narcotic analgesics. INTERVENTION Patients were randomly assigned to receive an intravenous infusion of purified poloxamer 188, 100 mg/kg for 1 hour followed by 30 mg/kg per hour for 47 hours (n = 127), or a matching volume of saline placebo (n = 128). MAIN OUTCOME MEASURE Duration of the painful episode, from randomization to crisis resolution. RESULTS Mean (SD) duration of the painful episodes was 141 (42) hours in the placebo group compared with 133 (41) hours in those treated with purified poloxamer 188, a 9-hour reduction (P =.04). Subset analyses indicated an even more pronounced purified poloxamer 188 effect in children aged 15 years or younger (21 hours; P =.01) and in patients who were receiving hydroxyurea (16 hours; P =.02). Finally, the proportion of patients achieving crisis resolution was increased by purified poloxamer 188 (65/126 [52%] vs 45/123 [37%]; P =.02). Similar results were observed in children aged 15 years or younger (22/37 [60%] vs 10/36 [28%]; P =.009) and in patients who were also receiving hydroxyurea (12/26 [46%] vs 4/28 [14%]; P =.02). CONCLUSIONS A decrease in the duration of painful episodes and an increase in the proportion of patients who achieved resolution of the symptoms were observed when the purified poloxamer 188-treated patients were compared with the patients receiving placebo. However, the difference between these groups was significant but relatively small. In subgroup analysis, a more significant effect on both parameters was observed in children and in patients who were receiving concomitant hydroxyurea. It is important to confirm both of these observations in further prospective trials.
Collapse
Affiliation(s)
- E P Orringer
- School of Medicine, University of North Carolina at Chapel Hill, Room 125, MacNider Bldg, CB7000, Chapel Hill, NC 27599-7000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Schuster V, Zeitler P, Seregard S, Ozcelik U, Anadol D, Luchtman-Jones L, Meire F, Mingers AM, Schambeck C, Kreth HW. Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis. Thromb Haemost 2001; 85:1004-10. [PMID: 11434676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Severe type I plasminogen deficiency has been recently linked to ligneous conjunctivitis, a rare and uncommon form of chronic conjunctivitis. In this study, eight unrelated ligneous conjunctivitis patients living in different parts of the world were examined. All affected subjects from which plasma was available displayed absent or markedly reduced plasminogen antigen and plasminogen functional activity. Molecular genetic studies of seven patients identified a Lys19-->Glu mutation in two boys in a homozygous state, and in two girls in a compound-heterozygous state in which the second plasminogen gene carried a missense (Arg134-->Lys) and a nonsense mutation (Cys133--> Stop), respectively. A fifth patient was shown to be homozygous for a frameshift mutation in plasminogen exon 14 (Gly565ins-G). In two unrelated subjects with ligneous conjunctivitis no mutations in the plasminogen gene were identified. Our results suggest that the Lys19-->Glu mutation is the most prevalent mutation in the plasminogen gene of patients with ligneous conjunctivitis.
Collapse
Affiliation(s)
- V Schuster
- Children's Hospital, University of Leipzig, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Ambrose TM, Parvin CA, Mendeloff E, Luchtman-Jones L. Evaluation of the TAS analyzer and the low-range heparin management test in patients undergoing extracorporeal membrane oxygenation. Clin Chem 2001; 47:858-66. [PMID: 11325889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
BACKGROUND The new Low-Range Heparin Management Test (LHMT), a method for point-of-care testing (POCT) of heparinization, has been designed to function at the low to moderate heparin concentrations typically found in patients undergoing extracorporeal membrane oxygenation (ECMO). In this study, the new method is compared with two POCT methods and a laboratory-based anti-Xa assay. METHODS We obtained 760 whole blood samples from 13 patients undergoing ECMO. All samples were tested immediately by the LHMT, the Activated Clotting Time (ACT) test, and its low-range counterpart (ACT-LR). Aliquots from the same blood draw were frozen for later anti-Xa analysis using the Diagnostica Stago method on the Roche Cobas Fara-II. RESULTS The precision was best for duplicate citrated LHMT samples (CV = 3.1%). LHMT clotting times (overall median, 162 s) were typically shorter than ACT or ACT-LR times (247 and 235 s, respectively). The relationship between the LHMT and the other POCT methods differed significantly from patient to patient (P <0.0001), and a meaningful single relationship between the methods could not be obtained. The overall correlation coefficient between clotting time values and actual heparin concentrations was < or = 0.48 for each of the instruments tested, although time plots of each analyzer's data suggested that they detected heparin dosage changes within single patients. CONCLUSIONS The performance of the LHMT on the TAS Analyzer is equivalent to that of currently commercially available POCT methods. The lack of agreement between absolute clotting time values and heparin concentrations suggests the need for reexamination of current ECMO patient management strategy.
Collapse
Affiliation(s)
- T M Ambrose
- Department of Pathology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | | | | | | |
Collapse
|
10
|
Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res 2001; 7:32-7. [PMID: 11205914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
A Phase I trial of irinotecan was performed to determine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), and the incidence and severity of other toxicities in children with refractory solid tumors. Thirty-five children received 146 courses of irinotecan administered as a 60-min i.v. infusion, daily for 5 days, every 21 days, after premedication with dexamethasone and ondansetron. Doses ranged from 30 mg/m2 to 65 mg/m2. An MTD was defined in heavily pretreated and less-heavily pretreated (i.e., two prior chemotherapy regimens, no prior bone marrow transplantation, and no radiation to the spine, skull, ribs, or pelvic bones) patients. Myelosuppression was the primary DLT in heavily pretreated patients, and diarrhea was the DLT in less-heavily pretreated patients. The MTD in the heavily pretreated patient group was 39 mg/m2, and the MTD in the less-heavily pretreated patients was 50 mg/m2. Non-dose-limiting diarrhea that was well controlled and of brief duration was observed in approximately 75% of patients. A partial response was observed in one patient with neuroblastoma, and in one patient with hepatocellular carcinoma. Stable disease (4-20 cycles) was observed in seven patients with a variety of malignancies including neuroblastoma, pineoblastoma, glioblastoma, brainstem glioma, osteosarcoma, hepatoblastoma, and a central nervous system rhabdoid tumor. In conclusion, the recommended Phase II dose of irinotecan administered as a 60-min i.v. infusion daily for 5 days, every 21 days, is 39 mg/m2 in heavily treated and 50 mg/m2 in less-heavily treated children with solid tumors.
Collapse
Affiliation(s)
- S Blaney
- Texas Children's Cancer Center/Baylor College of Medicine, Houston 77030, USA.
| | | | | | | | | | | | | |
Collapse
|
11
|
Horn B, Heideman R, Geyer R, Pollack I, Packer R, Goldwein J, Tomita T, Schomberg P, Ater J, Luchtman-Jones L, Rivlin K, Lamborn K, Prados M, Bollen A, Berger M, Dahl G, McNeil E, Patterson K, Shaw D, Kubalik M, Russo C. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol 1999; 21:203-11. [PMID: 10363853 DOI: 10.1097/00043426-199905000-00008] [Citation(s) in RCA: 153] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE The goal of this multi-institutional retrospective study of children with intracranial ependymoma was to identify risk factors associated with unfavorable overall survival (OS) and event-free survival (EFS). PATIENTS AND METHODS Clinical data, including demographics, tumor location, spread, histology, details of surgery, radiation treatment, and chemotherapy were collected. Clinical characteristics and univariate and multivariate analyses of risk factors for OS and EFS are presented. RESULTS Eleven U.S. institutions contributed 83 patients treated from 1987 to 1991. The OS at 5 and 7 years was 57% and 46%, and EFS at 5 and 7 years was 42% and 33%. Patients 3 years of age or younger differed from the older group by more common infratentorial location, less common gross total resection (GTR), and postoperative use of chemotherapy rather than radiation. This younger group of patients had worse survival (P < 0.01) than the older age group. Other than young age, less than GTR and World Health Organization (WHO) II grade 3 histology were significant adverse risk factors for EFS in univariate and multivariate analyses. OS shared the same adverse risk factors except for histology in multivariate analysis, which was only of borderline significance (P = 0.05). Progression at the original tumor location, present in 89% of patients, was the major pattern of tumor recurrence. Adjuvant chemotherapy in the group older than 3 years or craniospinal radiation in M0 patients did not significantly change EFS. CONCLUSIONS Adverse outcome in childhood intracranial ependymoma is related to age (3 years or younger), histology (grade 3), and degree of surgical resection (less than GTR). New approaches, particularly for local tumor control in younger patients, are needed to improve survival.
Collapse
Affiliation(s)
- B Horn
- UC/Stanford Health Care, San Francisco, California, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
In 1964, the events of haemostasis were organized into the intrinsic and extrinsic pathways by the cascade/waterfall hypothesis, with primary physiological importance being given to the intrinsic pathway. Recent experimental evidence, as well as information about the clinical course of patients with various coagulation factor deficiencies, indicates a more prominent role for tissue factor. Rediscovery of the plasma protease inhibitor, tissue factor pathway inhibitor, and new information about the activation of factor XI have supported a revised theory of coagulation.
Collapse
Affiliation(s)
- L Luchtman-Jones
- Department of Pediatrics/Division of Pediatric Hematology/Oncology, Washington University School of Medicine, St Louis, MO, USA
| | | |
Collapse
|